Buffington Mohr McNeal grew its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 100.5% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 19,350 shares of the company’s stock after acquiring an additional 9,700 shares during the quarter. Buffington Mohr McNeal’s holdings in Henry Schein were worth $1,481,000 as of its most recent SEC filing.
Other large investors also recently added to or reduced their stakes in the company. YorkBridge Wealth Partners LLC lifted its position in shares of Henry Schein by 5.2% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 570 shares of the company’s stock valued at $104,000 after acquiring an additional 28 shares during the period. Sun Life Financial INC lifted its position in shares of Henry Schein by 8,185.7% during the 2nd quarter. Sun Life Financial INC now owns 580 shares of the company’s stock valued at $106,000 after acquiring an additional 573 shares during the period. Lee Financial Co bought a new stake in shares of Henry Schein during the 2nd quarter valued at $161,000. Acrospire Investment Management LLC lifted its position in shares of Henry Schein by 150.0% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,000 shares of the company’s stock valued at $183,000 after acquiring an additional 600 shares during the period. Finally, HM Payson & Co. bought a new stake in shares of Henry Schein during the 2nd quarter valued at $204,000. Hedge funds and other institutional investors own 47.48% of the company’s stock.
A number of research firms have recently commented on HSIC. Stifel Nicolaus reissued a “hold” rating on shares of Henry Schein in a report on Thursday, July 6th. Credit Suisse Group reissued a “hold” rating and set a $80.00 price target on shares of Henry Schein in a report on Thursday, July 13th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $88.50 target price on shares of Henry Schein in a report on Friday, July 21st. BidaskClub cut Henry Schein from a “hold” rating to a “sell” rating in a report on Wednesday, August 2nd. Finally, Northcoast Research raised Henry Schein from a “neutral” rating to a “buy” rating and set a $109.00 target price for the company in a report on Monday, August 7th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and six have assigned a buy rating to the stock. Henry Schein presently has a consensus rating of “Hold” and a consensus price target of $92.89.
COPYRIGHT VIOLATION NOTICE: “Henry Schein, Inc. (HSIC) Stake Increased by Buffington Mohr McNeal” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.com-unik.info/2017/11/02/henry-schein-inc-hsic-stake-increased-by-buffington-mohr-mcneal.html.
In related news, SVP Paul Rose sold 2,126 shares of the business’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $172.51, for a total transaction of $366,756.26. Following the transaction, the senior vice president now owns 17,841 shares in the company, valued at approximately $3,077,750.91. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.19% of the stock is owned by insiders.
Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $0.88 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.86 by $0.02. Henry Schein had a return on equity of 19.91% and a net margin of 4.59%. The company had revenue of $3.06 billion for the quarter, compared to the consensus estimate of $3.05 billion. During the same quarter in the previous year, the business earned $0.82 EPS. Henry Schein’s revenue was up 6.4% compared to the same quarter last year.
Henry Schein declared that its Board of Directors has initiated a share repurchase plan on Monday, September 18th that allows the company to buyback $400.00 million in outstanding shares. This buyback authorization allows the company to reacquire up to 6.3% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board of directors believes its shares are undervalued.
Henry Schein Profile
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC).
What are top analysts saying about Henry Schein Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Henry Schein Inc. and related companies.